Hunan Shangkang Pharmaceutical E-commerce Co., Ltd. (hereinafter referred to as "Shangkang Pharmaceutical Network") is a B2B pharmaceutical e-commerce enterprise jointly funded by Quanzhou Group, a fortune 500 enterprise, and Hunan Branch of Industrial and Commercial Bank of China. Relying on modern information technology, Internet, Internet of Things, modern logistics management system and advanced logistics technology and equipment, Shangkang Medical Network is a large-scale vertical medical e-commerce platform integrating ERP, call center, mobile commerce, multimedia video and Shangkang Peony Card, which reduces circulation links for pharmaceutical suppliers and downstream end customers. Reduce procurement costs; Accelerate the turnover of products and funds; The second-generation pharmaceutical B2B e-commerce enterprise integrating supplier flow, logistics, capital flow and information flow.
As the first large-scale website for the wholesale of cheap drugs in China, it has received strong support from hunan food and drug administration, the Ministry of Commerce and the municipal government and departments of Hunan Province, and set sail smoothly. The emergence of Shangkang Medicine Network is considered by the industry to greatly reduce the circulation of drugs, improve the distribution efficiency and reduce the circulation cost, which is in line with the policy of price reduction and benefiting the people in the new medical reform.
Multi-link, high cost and drug batch call for a new model.
For a long time, the price of drugs in China has been unable to come down. The government has introduced a series of measures to reduce drug prices, but drug prices have remained high. The underlying reason is the long circulation time of drugs.
Since the reform and opening up, China's drug circulation industry has achieved rapid development. However, due to the disadvantages of the system formed in history, the whole drug circulation industry is scattered, small, chaotic and poor, and its business model and circulation efficiency are relatively backward, which does not match the production scale and consumption demand. It is necessary to establish a new circulation mode with low cost and high efficiency.
As far as the common phenomenon in the industry is concerned, drugs are sold by manufacturers to general distributors at ex-factory prices. After the general distributor, provincial agents, municipal agents, scattered wholesalers in cities and other links, the bottom wholesalers sell to hospitals through direct contact or bidding, with six or seven intermediate links.
The circulation expense rate of pharmaceutical intermediaries remains high, the profitability is low, and the loss of the industry is expanding. The gross profit margin of domestic large pharmaceutical wholesale enterprises is 6%, and the net profit margin is only 1%. The scale of drug sales in the United States is more than $400 billion, and the gross profit margin of the pharmaceutical circulation industry is about 4%, which is lower than the domestic level of 6%. However, due to its large scale and high concentration, its average expense ratio is about 2.9%, so its profitability is strong and its net interest rate is about 65,438+0%.
There are many drug circulation links in China, and the cost is high. Driven by the interests of medical institutions, how can the drug price be low after the drug circulation links are reversed?
Jiang Zengwei, Vice Minister of Commerce, said in an interview a few days ago that the pharmaceutical circulation industry is connected with pharmaceutical production at one end and medical institutions and patients at the other, which is an important link in the operation of the medical and health system and an important part of medical reform. The pharmaceutical circulation industry has developed well and can effectively cooperate with and serve the medical reform.
Shangkang Medicine Network is still a broken medicine market.
With the promulgation of "Twelfth Five-Year Plan for the Development of Drug Circulation Industry", how to promote the healthy development of drug circulation industry, reduce circulation links, really lower drug prices, and ensure people to eat convenient drugs and safe drugs will be the next very arduous task.
According to the research report of Forrester Market Research Company, the United States, as the birthplace of e-commerce, started drug e-commerce earlier, and saved as much as 1 1 billion dollars in the pharmaceutical market with annual sales of 83 billion dollars by relying on the Internet.
As the first batch network of cheap drugs in China, Shangkang Pharmaceutical Network has brought together suppliers, manufacturers, distributors and retailers of pharmaceutical raw materials from all over the country and the world through advanced online e-commerce platform and offline terminal promotion platform, and innovated the order system, fund settlement system and logistics distribution system, providing medical information, raw material procurement, pharmaceutical product procurement, financial financing, drug distribution, channel distribution, deep distribution, terminal management and other services.
Shangkang Pharmaceutical Network, fully reducing circulation links and striving to build Alibaba in the pharmaceutical industry will provide a new format for the pharmaceutical market to break.